Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen Macdonald

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Advance for Nurse Practitioners|January 31, 2009
ANCC responds to blog commentKaren Macdonald
Expert Opinion on Drug Safety|August 14, 2012
Clinical safety of biosimilar recombinant human erythropoietinsIvo Abraham, Karen MacDonald
JAMA Network Open|January 21, 2026
Valuing Frailty Prevention in Aging in the Post-QALY EraIvo Abraham, Karen MacDonald
Expert Opinion on Drug Safety|September 25, 2012
Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolationsIvo Abraham, Karen MacDonald
JAMA Dermatology|March 5, 2025
The Evolving Landscape of Biologics-Biosimilars, Biobetters, and BioparallelsIvo Abraham, Karen MacDonald
JAMA Dermatology|July 12, 2023
Exploring Discordance Between Patients and Clinicians-Understanding Perceived Disease SeverityJohn S Barbieri, Karen MacDonald
Leukemia Research|May 6, 2021
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaAli McBride, Karen MacDonald, Ivo Abraham
Progress in Transplantation (Aliso Viejo, Calif.)|December 7, 2018
A Cautionary Research Note on Standard Versus Extended Release TacrolimusIvo Abraham, Razan Alsheikh, Karen MacDonald
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Arguing (About) the Value of Cancer CareIvo Abraham, Ali McBride, Karen MacDonald
JAMA Network Open|March 23, 2023
Should a Systematic Review Be Required in a Clinical Trial Report? Perhaps, But Not YetIvo Abraham, Matthias Calamia, Karen MacDonald
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Advance for Nurse Practitioners|January 31, 2009
ANCC responds to blog commentKaren Macdonald
Expert Opinion on Drug Safety|August 14, 2012
Clinical safety of biosimilar recombinant human erythropoietinsIvo Abraham, Karen MacDonald
JAMA Network Open|January 21, 2026
Valuing Frailty Prevention in Aging in the Post-QALY EraIvo Abraham, Karen MacDonald
Expert Opinion on Drug Safety|September 25, 2012
Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolationsIvo Abraham, Karen MacDonald
JAMA Dermatology|March 5, 2025
The Evolving Landscape of Biologics-Biosimilars, Biobetters, and BioparallelsIvo Abraham, Karen MacDonald
JAMA Dermatology|July 12, 2023
Exploring Discordance Between Patients and Clinicians-Understanding Perceived Disease SeverityJohn S Barbieri, Karen MacDonald
Leukemia Research|May 6, 2021
Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaAli McBride, Karen MacDonald, Ivo Abraham
Progress in Transplantation (Aliso Viejo, Calif.)|December 7, 2018
A Cautionary Research Note on Standard Versus Extended Release TacrolimusIvo Abraham, Razan Alsheikh, Karen MacDonald
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Arguing (About) the Value of Cancer CareIvo Abraham, Ali McBride, Karen MacDonald
JAMA Network Open|March 23, 2023
Should a Systematic Review Be Required in a Clinical Trial Report? Perhaps, But Not YetIvo Abraham, Matthias Calamia, Karen MacDonald
Pageof 10